The pharmaceutical industry loses about 80% of a brand’s revenue within twelve months of generic entry. For a blockbuster generating […]

When AbbVie watched its first Humira biosimilar land on the US market in January 2023, the company had already spent

Branded generics — off-patent drugs sold under a proprietary name rather than an INN — are a $280 billion global

The compound is twenty years old. The molecule patent expires in eighteen months. Forty ANDA filers are lined up. The

When a brand-name drug loses patent protection, it typically sheds 80% of its revenue within 12 months. That is not

How the smartest pharmaceutical IP teams build exclusivity that outlasts the molecule by a decade — and what happens when

There is a class of pharmaceutical asset that rarely shows up in earnings calls but drives billions in brand revenue

Somewhere in a brand-name drug company’s lifecycle management plan, there is usually a line item that reads something like: ‘Evaluate

The FDA Orange Book publishes patent expiry dates. Analysts read them, model them into revenue forecasts, and brief executives on